Euroapi: big rise in net loss in 2023

(CercleFinance.com) - Euroapi reports a net loss of -E189.
7m for 2023, compared with -E15m in 2022, with a core EBITDA of E93.1m, representing a margin of 9.2% versus 12.3% the previous year.

The latter was penalised by less favourable absorption of fixed costs and inflation, while sales for the supplier of active pharmaceutical ingredients rose by 3.8% to E1.01bn (+3.1% at constant exchange rates).

For 2024, Euroapi anticipates a core EBITDA margin of between 6% and 9%, as well as sales falling by between 4% and 7% on a comparable basis, in particular due to lower sales to Sanofi.


Copyright (c) 2024 CercleFinance.com. All rights reserved.